Research programme: cancer therapeutics - PepTx

Drug Profile

Research programme: cancer therapeutics - PepTx

Alternative Names: 6DBF7; PTX 004; PTX 009; PTX 012

Latest Information Update: 22 Dec 2009

Price : $50

At a glance

  • Originator University of Minnesota
  • Developer PepTx; University Hospital Maastricht; University of Minnesota
  • Class Peptides
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 30 Jan 2008 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top